Matthew B. Rettig

13.8k total citations · 3 hit papers
171 papers, 6.5k citations indexed

About

Matthew B. Rettig is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Matthew B. Rettig has authored 171 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 107 papers in Pulmonary and Respiratory Medicine, 59 papers in Radiology, Nuclear Medicine and Imaging and 45 papers in Oncology. Recurrent topics in Matthew B. Rettig's work include Prostate Cancer Treatment and Research (101 papers), Radiopharmaceutical Chemistry and Applications (47 papers) and Prostate Cancer Diagnosis and Treatment (39 papers). Matthew B. Rettig is often cited by papers focused on Prostate Cancer Treatment and Research (101 papers), Radiopharmaceutical Chemistry and Applications (47 papers) and Prostate Cancer Diagnosis and Treatment (39 papers). Matthew B. Rettig collaborates with scholars based in United States, Canada and Germany. Matthew B. Rettig's co-authors include Jiabin An, Robert E. Reiter, Jiaoti Huang, Yiping Sun, Alan Lichtenstein, Dino Di Carlo, Myrna Fisher, Jérémie Calais, Allan J. Pantuck and Robert Vescio and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Advanced Materials.

In The Last Decade

Matthew B. Rettig

160 papers receiving 6.4k citations

Hit Papers

Highly Efficient Capture of Circulating Tumor Cells by Us... 2011 2026 2016 2021 2011 2013 2025 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Highly Efficient Capture of Circulating Tumor Cells by Using Nanostructured Silicon Substrates with Integrated Chaotic Micromixers
    2011 542 citations Shutao Wang, Kan Liu et al. profile →
  2. Size-selective collection of circulating tumor cells using Vortex technology
    2013 432 citations Matthew B. Rettig et al. profile →
  3. PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging
    2025 19 citations Adrien Holzgreve, Nicholas G. Nickols et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Matthew B. Rettig United States 45 2.4k 2.1k 2.0k 1.4k 1.3k 171 6.5k
Sunil Krishnan United States 52 3.3k 1.4× 2.4k 1.2× 2.1k 1.0× 1.0k 0.7× 1.7k 1.3× 154 8.8k
Joseph A. Ludwig United States 34 3.3k 1.3× 1.7k 0.8× 3.3k 1.7× 1.0k 0.8× 1.1k 0.9× 93 7.8k
Nicolaas A.P. Franken Netherlands 31 1.6k 0.7× 1.3k 0.6× 2.9k 1.5× 1.1k 0.8× 1.7k 1.3× 117 6.8k
Alexander D. Borowsky United States 51 2.6k 1.1× 1.3k 0.6× 4.7k 2.4× 1.6k 1.2× 988 0.8× 197 8.7k
Michael W. Epperly United States 47 1.1k 0.5× 1.8k 0.9× 3.6k 1.9× 1.2k 0.9× 578 0.4× 250 7.8k
Hans M. Rodermond Netherlands 23 2.9k 1.2× 868 0.4× 3.6k 1.9× 1.6k 1.1× 818 0.6× 60 7.1k
Michael Fiegl Austria 37 1.9k 0.8× 852 0.4× 2.3k 1.2× 1.1k 0.8× 796 0.6× 165 5.9k
Se Jin Jang South Korea 51 3.2k 1.3× 3.9k 1.9× 3.0k 1.5× 1.4k 1.1× 508 0.4× 277 9.2k
Eigo Otsuji Japan 53 2.6k 1.1× 3.7k 1.8× 5.0k 2.5× 3.8k 2.8× 652 0.5× 633 11.4k
Payal Kapur United States 43 1.3k 0.5× 2.7k 1.3× 2.8k 1.4× 1.5k 1.1× 464 0.4× 236 6.2k

Countries citing papers authored by Matthew B. Rettig

Since Specialization
Citations

This map shows the geographic impact of Matthew B. Rettig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew B. Rettig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew B. Rettig more than expected).

Fields of papers citing papers by Matthew B. Rettig

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew B. Rettig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew B. Rettig. The network helps show where Matthew B. Rettig may publish in the future.

Co-authorship network of co-authors of Matthew B. Rettig

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew B. Rettig. A scholar is included among the top collaborators of Matthew B. Rettig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew B. Rettig. Matthew B. Rettig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bailey, Adrian J., Lorna Kwan, Jeremy B. Shelton, et al.. (2025). Prostate cancer incidence and outcomes among Vietnam veterans receiving care in the Veterans Health Administration. Cancer. 131(15). e70007–e70007.
2.
Holzgreve, Adrien, Christine E. Mona, Xinmin Li, et al.. (2025). Liquid Biopsy of Circulating Tumor Cells and DNA in the Context of PSMA Radiopharmaceutical Therapy. Journal of Nuclear Medicine. 67(1). 12–14.
3.
Aggarwal, Rahul, Jacqueline Vuky, David James VanderWeele, et al.. (2025). Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology. 43(15). 1824–1834. 5 indexed citations
4.
Ly, Ann, Sara Rodríguez, Hanwei Zhang, et al.. (2024). PD-1 blockade plus cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancers. Cell Reports Medicine. 5(11). 101824–101824. 5 indexed citations
5.
6.
Rieger, Angela C., Andrea Farolfi, Amar U. Kishan, et al.. (2024). Prostate-Specific Membrane Antigen PET/CT–Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine. 65(9). 1387–1394. 6 indexed citations
7.
Rettig, Matthew B., John Shen, Robert E. Reiter, et al.. (2024). Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial. European Urology. 85(6). 517–520. 10 indexed citations
8.
Hao, Qiongyu, Susanne M. Henning, Clara E. Magyar, et al.. (2024). Enhanced Chemoprevention of Prostate Cancer by Combining Arctigenin with Green Tea and Quercetin in Prostate-Specific Phosphatase and Tensin Homolog Knockout Mice. Biomolecules. 14(1). 105–105. 6 indexed citations
9.
Romero, Tahmineh, Matthew B. Rettig, Michael L. Steinberg, et al.. (2022). Significant changes in macrophage and CD8 T cell densities in primary prostate tumors 2 weeks after SBRT. Prostate Cancer and Prostatic Diseases. 26(1). 207–209. 10 indexed citations
10.
Ferdinandus, Justin, Wolfgang P. Fendler, Jérémie Calais, et al.. (2020). Impact of 68Ga-PSMA-11 PET on the management of biochemically recurrent prostate cancer in a prospective single-arm clinical trial. European Urology Open Science. 19. e1215–e1216. 2 indexed citations
11.
Aggarwal, Rahul, David A. Quigley, Jiaoti Huang, et al.. (2019). Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity. Molecular Cancer Research. 17(6). 1235–1240. 40 indexed citations
12.
Li, Shangze, Ka-wing Fong, Galina Gritsina, et al.. (2019). Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer. Cancer Research. 79(10). 2580–2592. 92 indexed citations
13.
Montgomery, Bruce, Mario A. Eisenberger, Matthew B. Rettig, et al.. (2015). Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer. Clinical Cancer Research. 22(6). 1356–1363. 64 indexed citations
14.
An, Jiabin, Huiren Liu, Clara E. Magyar, et al.. (2013). Hyperactivated JNK Is a Therapeutic Target in pVHL-Deficient Renal Cell Carcinoma. Cancer Research. 73(4). 1374–1385. 45 indexed citations
15.
Zhao, Libo, Yi‐Tsung Lu, Fuqiang Li, et al.. (2013). Tumor Cell Isolation: High‐Purity Prostate Circulating Tumor Cell Isolation by a Polymer Nanofiber‐Embedded Microchip for Whole Exome Sequencing (Adv. Mater. 21/2013). Advanced Materials. 25(21). 2870–2870. 1 indexed citations
16.
Zhao, Libo, Yi‐Tsung Lu, Fuqiang Li, et al.. (2013). High‐Purity Prostate Circulating Tumor Cell Isolation by a Polymer Nanofiber‐Embedded Microchip for Whole Exome Sequencing. Advanced Materials. 25(21). 2897–2902. 133 indexed citations
17.
Wang, Shutao, Kan Liu, Jian Liu, et al.. (2011). Highly Efficient Capture of Circulating Tumor Cells by Using Nanostructured Silicon Substrates with Integrated Chaotic Micromixers. Angewandte Chemie. 123(13). 3140–3144. 62 indexed citations
18.
Pantuck, Allan J., Jiabin An, Huiren Liu, & Matthew B. Rettig. (2010). NF-κB–Dependent Plasticity of the Epithelial to Mesenchymal Transition Induced by Von Hippel-Lindau Inactivation in Renal Cell Carcinomas. Cancer Research. 70(2). 752–761. 77 indexed citations
19.
An, Jiabin, et al.. (2010). p120-Catenin Is Transcriptionally Downregulated by FOXC2 in Non–Small Cell Lung Cancer Cells. Molecular Cancer Research. 8(5). 762–774. 45 indexed citations
20.
Sartippour, Maryam, Navindra P. Seeram, Jian Yu Rao, et al.. (2008). Ellagitannin-rich pomegranate extract inhibits angiogenesis in prostate cancer in vitro and in vivo. International Journal of Oncology. 32(2). 475–80. 94 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sunil Krishnan Breakdown of academic impact, for papers by Joseph A. Ludwig Breakdown of academic impact, for papers by Nicolaas A.P. Franken Breakdown of academic impact, for papers by Alexander D. Borowsky Breakdown of academic impact, for papers by Michael W. Epperly Breakdown of academic impact, for papers by Hans M. Rodermond Breakdown of academic impact, for papers by Michael Fiegl Breakdown of academic impact, for papers by Se Jin Jang Breakdown of academic impact, for papers by Eigo Otsuji Breakdown of academic impact, for papers by Payal Kapur
Rankless by CCL
2026